Last reviewed · How we verify
Magnevist (SH L 451A)
Magnevist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.
Magnevist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications.
At a glance
| Generic name | Magnevist (SH L 451A) |
|---|---|
| Sponsor | Bayer |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Magnevist (gadopentetate dimeglumine) contains gadolinium, a paramagnetic metal ion that increases the relaxation rate of nearby water molecules, resulting in increased signal intensity on T1-weighted MRI images. This allows for improved visualization and differentiation of tissues and lesions during MRI examinations. The gadolinium is chelated with diethylenetriaminepentaacetic acid (DTPA) to improve safety and reduce toxicity.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including cardiovascular and abdominal applications
Common side effects
- Gadolinium retention in tissues
- Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment
- Injection site reactions
- Headache
- Dizziness
Key clinical trials
- Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis (PHASE3)
- Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnevist (SH L 451A) CI brief — competitive landscape report
- Magnevist (SH L 451A) updates RSS · CI watch RSS
- Bayer portfolio CI